Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

473 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.
Fanola CL, Morrow DA, Cannon CP, Jarolim P, Lukas MA, Bode C, Hochman JS, Goodrich EL, Braunwald E, O'Donoghue ML. Fanola CL, et al. Among authors: hochman js. J Am Heart Assoc. 2017 Oct 24;6(10):e005637. doi: 10.1161/JAHA.117.005637. J Am Heart Assoc. 2017. PMID: 29066436 Free PMC article.
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP; SOLID-TIMI 52 Investigators; Steen DL. O'Donoghue ML, et al. Among authors: hochman js. JAMA. 2014 Sep 10;312(10):1006-15. doi: 10.1001/jama.2014.11061. JAMA. 2014. PMID: 25173516 Clinical Trial.
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Hagström E, Harrington RA, Hochman JS, Koenig W, Krug-Gourley S, Mohler ER 3rd, Siegbahn A, Tarka E, Steg PG, Stewart RA, Weiss R, Östlund O, White HD; STABILITY Investigators. Wallentin L, et al. Among authors: hochman js. J Am Heart Assoc. 2016 Jun 21;5(6):e003407. doi: 10.1161/JAHA.116.003407. J Am Heart Assoc. 2016. PMID: 27329448 Free PMC article. Clinical Trial.
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Östlund O, Wallentin L; STABILITY Investigators. Held C, et al. Among authors: hochman js. J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077. J Am Heart Assoc. 2017. PMID: 29066452 Free PMC article. Clinical Trial.
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events.
White HD, Stewart RAH, Dalby AJ, Stebbins A, Cannon CP, Budaj A, Linhart A, Pais P, Diaz R, Steg PG, Krug-Gourley S, Granger CB, Hochman JS, Koenig W, Harrington RA, Held C, Wallentin L; STABILITY Investigators. White HD, et al. Among authors: hochman js. Am Heart J. 2020 Jul;225:97-107. doi: 10.1016/j.ahj.2020.04.004. Epub 2020 Apr 18. Am Heart J. 2020. PMID: 32480059
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
Guimarães PO, Granger CB, Stebbins A, Chiswell K, Held C, Hochman JS, Krug-Gourley S, Lonn E, Lopes RD, Stewart RAH, Vinereanu D, Wallentin L, White HD, Hagström E, Danchin N. Guimarães PO, et al. Among authors: hochman js. J Am Heart Assoc. 2017 Sep 14;6(9):e006695. doi: 10.1161/JAHA.117.006695. J Am Heart Assoc. 2017. PMID: 28912210 Free PMC article. Clinical Trial.
Cardiogenic Shock After Acute Myocardial Infarction: A Review.
Samsky MD, Morrow DA, Proudfoot AG, Hochman JS, Thiele H, Rao SV. Samsky MD, et al. Among authors: hochman js. JAMA. 2021 Nov 9;326(18):1840-1850. doi: 10.1001/jama.2021.18323. JAMA. 2021. PMID: 34751704 Free PMC article. Review.
Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
Mega JL, Hochman JS, Scirica BM, Murphy SA, Sloan S, McCabe CH, Merlini P, Morrow DA. Mega JL, et al. Among authors: hochman js. Circulation. 2010 Apr 27;121(16):1809-17. doi: 10.1161/CIRCULATIONAHA.109.897231. Epub 2010 Apr 12. Circulation. 2010. PMID: 20385930 Clinical Trial.
Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock.
Samsky M, Krucoff M, Althouse AD, Abraham WT, Adamson P, Aguel F, Bilazarian S, Dangas GD, Gilchrist IC, Henry TD, Hochman JS, Kapur NK, Laschinger J, Masters RG, Michelson E, Morrow DA, Morrow V, Ohman EM, Pina I, Proudfoot AG, Rogers J, Sapirstein J, Senatore F, Stockbridge N, Thiele H, Truesdell AG, Waksman R, Rao S. Samsky M, et al. Among authors: hochman js. Am Heart J. 2020 Jan;219:1-8. doi: 10.1016/j.ahj.2019.10.006. Epub 2019 Nov 7. Am Heart J. 2020. PMID: 31707323 Free PMC article. Review. No abstract available.
473 results